SavedAdd your journal

Journals / Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi / 2020 / Cilt: 25 - Sayı: 3

The use of Hydroxychloroquine in the Treatment of COVID-19

COVID-19 Tedavisinde Hidroksiklorokin Kullanımı

Kamer TECEN YÜCEL
EMRE KARA
Kutay DEMİRKAN
Serhat ÜNAL
Pages
283–291
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The purpose of this article was to review the pharmacological properties and mechanism of COVID-19 treatment with hydroxychloroquine and its potential use on the current COVID-19 pandemic.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:COVID-19 is a newly emerging human infectious disease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) origin described as a pandemic by the World Health Organisation (WHO) on March 11, 2020.
📊
Key Findings & Data:There is currently no definitive cure for COVID-19; however, among the many treatment strategies, hydroxychloroquine has been suggested as a potential treatment.
💡
Conclusion & Impact:The purpose of this article was to review the pharmacological properties and mechanism of COVID-19 treatment with hydroxychloroquine and its potential use on the current COVID-19 pandemic.
🔬Design:Review & Systematic Survey
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters

Abstract

COVID-19 is a newly emerging human infectious disease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) origin described as a pandemic by the World Health Organisation (WHO) on March 11, 2020. There is currently no definitive cure for COVID-19; however, among the many treatment strategies, hydroxychloroquine has been suggested as a potential treatment. The purpose of this article was to review the pharmacological properties and mechanism of COVID-19 treatment with hydroxychloroquine and its potential use on the current COVID-19 pandemic.

Özet

COVID-19, şiddetli akut solunum yolu sendromu koronavirüs 2 (SARS-CoV-2) kaynaklı yeni ortaya çıkan bulaşıcı bir hastalıktır. DünyaSağlık Örgütü (DSÖ) tarafından 11 Mart 2020’de pandemi olarak tanımlanmıştır. Şu anda COVID-19 için kesin bir tedavi yoktur, ancaktedavi stratejileri arasında hidroksiklorokin potansiyel tedavi olarak önerilmektedir. Bu makalenin amacı, hidroksiklorokinin farmakolojiközelliklerini, COVID-19 tedavisindeki mekanizmasını ve mevcut COVID-19 salgını üzerindeki potansiyel kullanımını gözden geçirmektir.

🔖

Cite This Article

YÜCEL, K. T., KARA, E., DEMİRKAN, K., ÜNAL, S. (2020). The use of Hydroxychloroquine in the Treatment of COVID-19. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, Cilt: 25 - Sayı: 3, 283–291. https://ajindex.com/articles/348068

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Takeda K, Shigematsu T, Shirai M, Yamagiwa K, Amamori K, Sunda K, et al. Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy. Gan To Kagaku Ryoho 2012;39(Suppl. 1):74-6
  2. Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. Current pharmacological treatments for COVID-19: What’s next? Br J Pharmacol 2020;10.1111/ bph.15072
  3. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
  4. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases 2019;78:736-45
  5. Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases 2019;78:1296- 304
  6. Brito-Zerón P, Ramos-Casals M. Advances in the understanding and treatment of systemic complications in Sjögren’s syndrome. Curr Opin Rheumatol 2014;26:520-7
  7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506
  8. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62
  9. Mehra MR, Ruschitzka F, Patel AN. Retraction Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020;395:1820
  10. Pareja-Coronel A. Treatment of viral hepatitis with chloroquine. Am J Gastroenterol 1963;39:288-98
  11. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 2004;323:264-8
  12. Rolain J-M, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 2007;30:297-308
  13. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis 2003;3:722-7
  14. Han Y, Pham HT, Xu H, Quan